Try our Advanced Search for more refined results
Life Sciences - March, 2014
315 articles
- Eli Lilly Blocks Teva From Selling Generic Alimta
- Fed. Circ.'s Claim Construction Rule At Stake In Teva Case
- Justices Leave FCA Pleading Dispute To Circuits, For Now
- Fed. Circ. Snubs Patent Appeal Over Allergan Pinkeye Drug
- How Changes To 'Dear Doctor Letters' Will Impact Industry
- J&J Accepts $4B Carlyle Offer For Blood-Testing Unit
- Insurer Hits CVS With False Scripts Whistleblower Suit
- Fed. Circ. Says Generics Deals Exclude Endo's New Patents
- Patterson Belknap Can't Dump Surgical Stapling IP Suit
- Female Powerbrokers Q&A: Roetzel's Lori Heyer-Bednar
- Female Powerbrokers Q&A: Brownstein's Ellen Schulhofer
- High Court Agrees To Hear Teva MS Drug Patent Suit
- Warner Chilcott Bone Drug Patents Invalid, Judge Rules
- Sterigenics, PE Parent Spend $727M To Take Over Nordion
- Mass. Bans Painkiller Zohydro Until Abuse Is Addressed
- Hospira To Pay $60M To Settle Shareholder Class Action
- 6th Circ. Affirms Dismissal Of BioMimetic Shareholder Row
- Calif. Bill For Statewide Drug Disposal Program Advances
- GMO Food Fight: The Latest From The States And Feds
- FTC Eyes $1B Pay-For-Delay Win, Official Quips
- Pa. Appeals Court Won't Reconsider Asbestos Suits' Transfer
- Apotex Says It Doesn't Need To Re-Prove Cephalon Deceit
- Fed. Circ. Nixes Shire Win In Generic Lialda Case
- J&J Can't Avoid Class Action Over Aveeno 'Natural' Claims
- FDA Chief Questioned Over Staff Meeting With Trial Lawyers
- Female Powerbrokers Q&A: Pillsbury's Susan Serota
- Female Powerbrokers Q&A: McDermott's Effie Silva
- Condo Roccia Adds Ex-Kessler Topaz Patent Litigation Atty
- As E-Discovery Goes Global, Japan And South Korea Catch Up
- NY High Court Lets Biotronik Pursue Recall-Related Damages
- Novartis, Others To Curb Antibiotic Use In Livestock
- ITC Won't Invalidate Patent In Sleep-Aid Device Probe
- FDA Rips Med Device Co.'s Failure To Report Injuries
- Jury Charge Botched In Fen-Phen Fraud Case, 3rd Circ. Told
- Is The Misappropriation Theory Of Insider Trading Dead?
- Vitamin Shoppe Hit With Class Suit Over Enzyme Claims
- Legal Needs To Rethink Its Dropbox Account
- GSK Warns Of Tampering With Weight Loss Drug
- Female Powerbrokers Q&A: FordHarrison's Tiffany Downs
- Female Powerbrokers Q&A: Gruber Hurst's Shonn Brown
- How Law Firms Can Stay Profitable While Clients Cut Costs
- Life Sciences Should Brace For Fla. Rad Source Ruling
- High Court Changed Hatch-Waxman Cases — Nobody Noticed
- Schiff Nutrition Pays $5M In Dietary Supplement Labeling Row
- Pfizer Fails To Get Geodon Off-Label Use Case Tossed
- Merck Escapes Some Injury Claims In Fosamax MDL
- Vista Drops Suit Against Illumina Over $9B Roche Bid
- Merck $250M Sex Bias Suit Not Another Dukes, Plaintiffs Say
- 2 Firms Steal GC Hearts In Health, Pharma
- GSK Handed $106M Verdict For Paxil Generic Contract Breach
- Extra ACA Enrollment Time Boosts Health Care Industry
- J&J May Have Destroyed Vaginal Mesh Docs, DOJ Told
- Female Powerbrokers Q&A: Farella Braun's Mary McCutcheon
- Female Powerbrokers Q&A: Drinker Biddle's Jill Bronson
- Foley & Lardner Adds Ex-Nelson Mullins Health Atty In Fla.
- PhRMA Slams FTC's Rationale For Targeting Drugmakers
- Inyx CEO Sues Berger Over Liens For Unpaid Legal Fees
- Finnegan Trademark Pro Heads To Pierce Atwood
- Uncertain Future For Products Containing Mercury
- Justice Kennedy Holds Strings In ACA Contraception Case
- Leveling The Playing Field For Small Business
- FDA Lays Out Pediatric Study Requirements For Device Makers
- And Now A Word From The Panel: Snow Day!
- Immunomedics, UC End Spat Over Antibody Product IP
- Deals Rumor Mill: Merck, BlackBerry, Jun He
- Stryker, Alliant Pay $1M To Settle Qui Tam Suit Over VA Sales
- The Prolific Pragmatist: Judge Richard Posner
- Punitive Damages In Play In Pa. Risperdal Cases, Court Hears
- Female Powerbrokers Q&A: Labaton's Martis Alex
- Female Powerbrokers Q&A: Dinsmore's Joanne Schreiner
- FDA Cites Another Indian Drugmaker For Suspect Records
- Justices Mull Limits Of Religious Protection In ACA Case
- Watson Gets $17.8M Jolt For Medicaid Drug Pricing
- Little-Used Doctrine Bars Brain Life's IP Claims: Fed Circ.
- Colo. Justices Give Attys Way To Advise On Marijuana Law
- EU Scientists Begin Vaginal Mesh Safety Investigation
- Teva's Planned Generic Infringes Mylan Patents, Judge Says
- High Court Stays Mum On Teva MS Drug Patent Suit
- High Court Won't Hear Miss. Medical Equipment Tax Row
- Attys Size Up High Court's Stance On Contraception Case
- Testim Suits Bubble Up Against Auxilium in Pa.
- Bayer Can't Get Tolling Ruling Nixed In $100M Sex Bias Suit
- Md. High Court Slaps WL Gore With $29M Tax Bill
- Feds Say Ex-SAC Trader's Acquittal Bid Distorts Facts
- Perrigo Sues FDA For Failing To Publish Approval Of Gel
- Herbalife To Give Icahn 3 More Board Seats
- FDA Details Label Development For Fast-Tracked Drugs
- Female Powerbrokers Q&A: Perkins Coie's Susan Foster
- Female Powerbrokers Q&A: Gibson Dunn's Helgi Walker
- District Courts Grapple With High Court's Actavis Ruling
- Technology — Not Just For The Privileged Anymore
- 4 Elite New York Law Firms Keep Partner Ranks Lean
- NY, Chicago Home To Most Law360 400 Firms
- Jones Day Lands Top Spot In Law360 400
- In BigLaw, The Big Keep Getting Bigger
- Law360 Reveals 400 Largest US Law Firms
- J&J Ruling Removes FDA Warnings From Plaintiff Playbook
- Saline Shortage Demands Faster Fix, Hospitals Tell FDA
- ITC Launches Probe Of Dentsply Lithium Silicate Imports
- Medical Device Recalls Doubled Over Past Decade, FDA Says
- Novartis Defeats Ore. Aredia, Zometa Jaw Injury Suit
- UK's Mobile Medical Apps Guidance Parallels FDA's
- Pfizer Beats FCA Suit Over Pain Patch Marketing
- Deals Rumor Mill: Temasek, Danone, Air Berlin
- Texas Atty Wards Off $10M Fen-Phen Overbilling Judgment
- 9 High Court Questions To Watch For In Contraception Case
- Female Powerbrokers Q&A: Munger Tolles' Kristin Myles
- Female Powerbrokers Q&A: Glaser Weil's Patty Glaser
- Teva Bashes Buyers' Expert In Bid To Uphold Antitrust Win
- Avoid Inducement Liability With Early Opinion Of Counsel
- How To Reduce Risk, Make More Money In Contingency Cases
- Akin Gump Snags Ex-McDermott Patent Pro In Calif.
- Ex-Employee Calls For Sanctions In Fresenius FCA Suit
- Judge Blows Smoke On LA Pot Shops' Equal Protection Suit
- Proskauer Nabs Antitrust Pro For DC Office
- Sanofi Sues Alkem Over Generic Heart Medication
- KV Pharma Reaches $12.8M Deal To Settle Shareholder Action
- Wal-Mart, Others Dispensed Expired Meds, FCA Suit Says
- Actavis, Noven Reach Deal Over Generic ADHD Patch Plans
- Ark. High Court Overturns J&J's $1.2B Risperdal Fine
- Mayroy Sells 7% Stake In French Pharma Co. Ipsen
- Health Cos. Want Pa. Hospital's Antitrust Suit Dismissed
- Female Powerbrokers Q&A: Thompson Hine's Kathie Brandt
- Female Powerbrokers Q&A: Day Pitney's Beth Sher
- Medicaid Enforcement: 10 Areas To Watch
- Hawaii AG Sues Plavix Makers For Deceptive Marketing
- Whistleblower's Cephalon FCA Suit Headed To Pa. Court
- Geron Faces Investor Suit After FDA Halts Clinical Trial
- Sens. Seek More Clarity On FDA's Mobile Medical App Stance
- Stereotaxis Ducks Investor Suit Over Product Projections
- Volcano Doesn't Owe $27M On Artery Device, Judge Hears
- Deals Rumor Mill: Michael Foods, Carlyle, Blackstone
- Former Stago Director Says He Was Fired For Whistleblowing
- Alcon Can't Escape Oversize Drug Bottle Class Action
- Horizon Inks $660M Deal For Specialty Drugmaker
- Female Powerbrokers Q&A: Lindquist's Nancy Vollertsen
- Female Powerbrokers Q&A: Dentons' Jana Cohen Barbe
- The Merry Crusader: Judge Jed Rakoff
- Celgene Ducks Teva Unit's Breast-Cancer Drug IP Claims
- Eli Lilly Slams Bid To Dredge Up Zyprexa Past In Actos Row
- Antitrust Group Backs Cipro Buyers In Pay-For-Delay Row
- St. Jude Topples Volcano In Guide Wire IP Feud
- Win For Barr In Glaucoma Drug IP Suit Upheld By Fed. Circ.
- Pfizer Files 2 Suits To Block Torrent's Generic Viagra
- Biolitec Hit With $75M Judgment In IP Indemnification Feud
- McDermott Nabs Finnegan Patent Ace To Bolster DC Office
- FDA Rips Compounders Making Unapproved J&J Drug
- Exxon, BMS, Others Settle With Feds Over NJ Superfund Site
- Female Powerbrokers Q&A: Wolf Greenfield's Helen Lockhart
- Female Powerbrokers Q&A: Labaton's Christine Azar
- FDA Hammers Columbia Doc's Clinical Trial Oversight
- High Court Deals Major Blow To Criminal Defendants
- GTCR Invests $300M Into New Life Sciences Acquisition Co.
- Cephalon Slaps Dr. Reddy's With Suit Over Leukemia Drug
- Dilemmas Remain For Colo. Attorneys After Amendment 64
- Savient Gets Nod For Ch. 11 Disclosure Statement
- Texas Appeals Court Nixes Attys' Fees In Employment Fight
- FDA Floats Guidance On Medical Devices For Rare Diseases
- NJ High Court To Mull Protections For Watchdog Workers
- Sanofi Hit With $20M Suit Over Osteoarthritis Cream
- CORRECTED: Patent Theft Trial Over McDermott Docs Settles
- FDA Updates Active Ingredient Guidance For New Drug Studies
- Wholesalers Ask 2nd Circ. To Toss Shire Pay-For-Delay Win
- Female Powerbrokers Q&A: Hangley's Ashely Chan
- Female Powerbrokers Q&A: Greenberg Traurig's Lori Cohen
- Law Firms Of The Future Will Be The Lawyers Of The Past
- Sorry Fido, NJ Medicine Tax Breaks For Humans Only
- Think Before You Blog: 8 Considerations For Attorneys
- Forest Pays Up To $10M In MDL Over Celexa, Lexapro
- Lawmakers Want To Undo FDA's Approval Of New Painkiller
- Forest Labs Hit With Suit Over Antidepressant Marketing
- Comcast Doesn't Doom Avandia Insurer Class, Judge Told
- Ill. 'Innovator Liability' Case Is Setback For Drug Cos.
- Allen Matkins Aids $106M Buy Of South Lake Union Property
- NAD Refers Diet Supplement Maker's Ad Claims To FTC
- Herbalife Delays Annual Meeting To Continue Icahn Talks
- Female Powerbrokers Q&A: Orrick's Denise Mingrone
- Female Powerbrokers Q&A: Frankfurt Kurnit's Victoria Cook
- Allergan Exec Bonus Suit Should Be Axed, Judge Says
- NY AG's 'Antitrust Boutique' Shows No Signs Of Slowing
- Tough Corporate Tax Outlook Fueling 'Inversion' Deals
- Fed. Circ. Unimpressed By Stem Cell Patent Standing Claims
- Facebook Slap Shows FDA Has Eagle Eye On Social Media
- Boehringer Hit With New Sanctions In Pradaxa MDL
- FDA Chief Defends Hydrocodone Painkiller Approval
- BNLfood's Injunction Bid Revived In Baby Formula Row
- Landauer Gets Nod To Solicit Votes For Ch. 11 Plan
- Another Forest Investor Says $25B Actavis Offer Is Weak
- FDA Blackballs Sun Pharma Plant In Import Safety Crackdown
- Conn. Gov. Pushes $450M Tax Reform Package
- Calif. High Court Preserves $415M Verdict Against Actelion
- Safety Worries Prompt FDA Update On Injectables Dosing
- NJ Judge Higbee Promoted From Mass Torts To Appeals Court
- Female Powerbrokers Q&A: Alston Hunt's Louise Ing
- Female Powerbrokers Q&A: Foley's Mary Braza
- K&L Gates Lands Kilpatrick IP Pro For DC Office
- EV3 Asks Del. Court To Undo Appriva Investors' $250M Award
- Judge Invalidates Reissue Patent For Pfizer's Celebrex
- Pharmacies, AGs Claim Sides On FDA's Generic Label Plan
- Facebook Page Lands Drugmaker In Hot Water With FDA
- NJ, Fla. To Get Slices Of $22M Genzyme FCA Settlement
- FTC Gives Nod To $4.3B Dainippon-Edison Pharma Deal
- Whistleblower Urges High Court To Take Takeda FCA Case
- Fed. Circ. Denies Becton $1.9M Extra Fees In TheraSense Row
- Deals Rumor Mill: AT&T, KKR, Cars.com
- FTC To Investigate Herbalife Pyramid-Scheme Claims
- Activist Investor Says Herbalife Is Violating Chinese Law
- Female Powerbrokers Q&A: Lindquist's Barbara Rummel
- Female Powerbrokers Q&A: Katten's Shannon Broome
- Reed Smith Atty's Widow Gives Generic-Drug Plaintiffs Hope
- How They Won It: Kaye, Munger Ward Off Pay-For-Delay Case
- Baxter Asks High Court To Mull USPTO's Verdict-Nixing Power
- Medicare Part D Defeat Shows Perils Of Agency Overreach
- FTC Says It Can Place HSR Act Restrictions On Drug Cos.
- NJ Jury Orders Roche To Pay $1.5M For Accutane User's IBD
- Ending Physician Speaker Programs May Not Be A Good Thing
- IPR: A 2nd Bite At The Apple For Hatch-Waxman Litigants
- Fed. Circ. Says Medtronic Didn't Infringe Defibrillator Patents
- Teva Pays $27M To End Antipsychotic Drug Kickback Claims
- Female Powerbrokers Q&A: McCarter & English's Pastor
- Female Powerbrokers Q&A: Thompson Hine's Goldstein
- Myriad Loses Bid To Block Ambry Cancer Tests In Patent Row
- FDA Is Evolving On New Chemical Entity Exclusivity
- Teva Can't Dodge GSK's Wellbutrin False Ad Suit
- Fed. Circ. Affirms For Promega In DNA Analysis Patent Row
- Teva Prods High Court Amid Venue Fight In Painkiller Suit
- Feds Scrap Controversial Medicare Part D Changes
- Agilent Can't Get Rival's DNA Patent Ruled Invalid
- Sens. Want Probe Into Zohydro 'Pay To Play' Meetings
- J&J Unit To Pay $5.9M To End Mont. Risperdal Row
- Eli Lilly Beats Zyprexa Failure-To-Warn Suit In 8th Circ.
- GSK Spends $1B On Additional Stake In India Pharma Unit
- Female Powerbrokers Q&A: Manatt's Linda Goldstein
- Female Powerbrokers Q&A: Nossaman's Yuliya Oryol
- 10 Problems In The USPTO's New Training Memo
- Roche Defends Accutane Against New Evidence In NJ Retrial
- J&J Unit Hit With $3M Jury Verdict In Topamax Row
- Abbott, Shareholders Agree To Settle Depakote Marketing Suit
- Judge Mulls Revival Of Nexium Pay-For-Delay Row
- Deals Rumor Mill: Vivendi, Vodafone, InterMune
- 1000s Target Medicare Part D Changes
- Zyprexa Fines Irrelevant In Actos Trial, Eli Lilly Says
- DC Circ. Opens Door For Stem Cell Regulation By FDA
- Novartis Keeps Aredia, Zometa Suit In Calif. Federal Court
- China's Latest Merger Decision Reflects New Approach
- Female Powerbrokers Q&A: Edwards Wildman's Brown
- Female Powerbrokers Q&A: Greenberg Traurig's Mitchell
- PE-Backed Biomet Plans $100M IPO To Trim Debt
- How To Avoid Discovery Problems While Using The Cloud
- Justices Told Pom Juice Spat Shouldn't Affect Drug Labels
- Agilent Says Rival's DNA Patent Based On Law Of Nature
- AbbVie Pushes Fed. Circ. To Resurrect Antibody Patent Spat
- J&J Antibacterial Drug Risky For Pneumonia Patients: FDA
- Pharmacies Fear Tort Fallout From New Drug Labeling Rule
- $100M Deal In Meningitis Outbreak MDL Nears Finish Line
- Insurer Must Defend Distributor In W.Va. AG's Pill Mill Suit
- Daiichi Must Reveal Worker Contact Info In Sex Bias Suit
- Female Powerbrokers Q&A: Foley's Jill Nicholson
- Female Powerbrokers Q&A: Squire Sanders' Caroline Noblet
- Important Conflict Being Overlooked In Omnicare Case
- Roche, Novartis Fined $250M Over Drug Collusion In Italy
- USPTO May Reject Wide Range Of Patents Under New Rules
- Dems Side With FDA On Generic Drug Labeling Overhaul
- SC's Off-Label Marketing Suit Against Cephalon To Continue
- Ark. Generic Reglan Suit Tossed Following 8th Circ. Remand
- Schumer Wants HHS To Overrule FDA's Painkiller Approval
- More Contract Pharmacy Oversight For HHS 340B Program
- Forest Escapes Lexapro Marketing Class Action
- Eli Lilly, Boehringer Diabetes Drug Faces FDA Roadblock
- Novartis Sues Pharmaceuticals International Over Zometa IP
- 5 Takeaways From FDA's Off-Label Promotion Guidance
- Female Powerbrokers Q&A: Sedgwick's Anna Shimko
- Female Powerbrokers Q&A: Robins Kaplan's Tara Sutton
- Anonymous Blog Post Hurt Drug Co.'s Stock, Petition Says
- J&J Unit Fights Use Of New Topamax Label In Defect Suits
- Wiggin & Dana Boosts IP Practice With 4 New Partners
- The King Of Late Night: Judge Robert Gerber
- Venable Lures Consumer Products Atty From Arnold & Porter
- Endo Faces Multistate Inquiry Over Pelvic Mesh Products
- FDA Sticks To Guns In Final Guidance On Production Changes
- 8 Highlights From Obama's $77B HHS Budget Plan
- FDA Warns 3 Drug Compounders Over Sloppy Practices
- Tyco Can't Ditch Suit Over $60M Eli Lilly Warehouse Heist
- Lab That Froze Ted Williams' Head Fights Tell-All Book
- Generic Drug Cos. Push To Ax FTC Pay-For-Delay Suit
- J&J Unit's Topamax Warnings Were Inadequate, Jury Told
- FDA Custom Device Exemption Still Won't See Much Use
- GSK Can't Escape Suit Over Reed Smith Atty's Suicide
- Amarin Targets AstraZeneca In Suit Over Heart Medication
- HHS OIG Finds Inadequate Fraud Info Amid CMS Data Issues
- FCA Claimants Closely Watching For Direction On Rule 9(b)
- NJ Biotech Co. Can't Dodge Former CFO's Exit Package
- Tax Creativity Keeps Pot Industry Out Of IRS Hot Water
- Baker Botts Adds 2 Gov't Contracts Attys To DC Office
- Female Powerbrokers Q&A: K&L Gates' Liz Thomas
- Female Powerbrokers Q&A: Paul Hastings' Palmina Fava
- As Legal Profession Evolves, GCs Outpace The Norm
- Ex-DLA Piper Atty To Co-Lead Paul Hastings' Tech Deals Team
- Securities Defense Bar Has High Hopes Riding On Omnicare
- Pressure Mounts To Scrap Medicare Part D Changes
- Medtrica, Steris Prevail In Endoscopy Kit Patent Dispute
- High Court Won't Put DuPont On $18M Hook Over Enzyme IP
- Plaintiffs Accuse Lilly Of Perjury, Seek Actos Trial Win
- FDA Looks To Social Media To Monitor Product Hazards
- Health Plan Doesn't Need Cost Study For Drug Prices: Panel
- Nexium Buyers Urge Judge To Rethink Ranbaxy Win In MDL
- Texas Bar Fights Fraudster's High Court Disbarment Appeal
- Female Powerbrokers Q&A: Kaye Scholer's Rhonda Trotter
- Female Powerbrokers Q&A: Cooley's Barbara Borden
- Fat Loss Pill Maker Defeats Cert. Bid In False Ad Suit
- Another Court Rules FCA Isn't For Regulatory Violations
- Ear-Cleaning Product Marketer Accused Of False Advertising
- Deals Rumor Mill: Vivendi, J. Crew, Unilever
- Bogus 'Derived From Beet' Ads Duping Buyers, Suit Says
- High Court Agrees To Hear Omnicare Securities Case